Biocon signs pact with Mexican firm for rh-Insulin

Biotechnology major Biocon today said its wholly-owned subsidairy has entered into a co-development and commercialisation agreement with Mexico's Laboratories PiSA SA de CV for generic recombinant human insulin for the US market.
"The company has, through its wholly owned subsidairy Biocon SA, entered into a co-development and commercialisation agreement with Laboratories PiSA SA de CV of Mexico for generic recombinant human insulin (rh-Insulin) for the US market," Biocon said in a BSE filing.
It further said: "This is a cost sharing and profit sharing agrement with Biocon SA being responsible for clinical development, regulatory approvals and commercialisation of the product in the US. The drug substance will be made by Biocon while the drug product will be made by PiSA at its facility in Mexico."

Shares of Biocon were trading at Rs 468, down 1.24 per cent, from the previous close on BSE.